...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Problems in Cancer >Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases
【24h】

Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases

机译：

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Breast cancer (BC) is the second most cause of central nervous system (CNS) metastases. Studies report that almost one third of patients (pts) with triple-negative, one-third with human epidermal growth fac-tor receptor 2 (HER2)-positive and 15 of those with hormone receptor-positive, HER2-negative metastatic breast cancer will develop brain metastases. It is known that the development of symptomatic brain metas-tases in women with advanced breast cancer is associated with poor prognosis, irrespective of local and systemic treatments. In the present study, we aim to determine the association between BC subtypes and CNS metastases occurrence and prognosis. Retrospective analysis of 309 BC patients with CNS metastases, confirmed by pathological and/or radiological methods, treated in a Cancer Center between 2003 and 2021, was obtained to identify clinicopathologic factors associated with early onset of brain metastases and sur-vival outcomes. For analysis purposes, 3 BC subtypes were considered according to hormone receptor status and HER-2 expression: ER and/or PR positive, HER-2 positive and triple negative. The median time between diagnosis of BC and detection of CNS metastases was 43 months, and it was significantly shorter in triple negative group (8 months). Twenty-one patients (6,8) had CNS metastases at BC diagnosis, with CNS be-ing the first site of recurrence in 35,3, mainly in HER2 positive. Most of the patients had parenchymal metastases (n = 245) and 37 (12) had leptomeningeal (LM) disease, with predominance in ER and/or PR positive subtype (70,3). In patients submitted to CNS surgery, the concordance between primary tumor and metastases subtype was higher in triple negative (76,9) compared to 63,2 in HER-2 positive and 38,9 in ER and/or PR positive group (P < 0.05). After CNS involvement, 25,4 (n = 34) of patients with triple negative disease did not receive any systemic therapy, compared to 30,6 ( n = 41) in HER-2 positive and 44 ( n = 59) in ER and/or PR positive groups ( P = 0.05). Median survival after CNS metastases was 9 months, but significantly longer in HER-2 positive group (16 months) and in patients submitted to surgical resection of CNS metastases, irrespectively of subtype (22 months vs 5 months in other treatment modali-ties). In multivariate Cox regression analysis, having HER-2 positive tumor was an independent prognostic factor for increasing survival after CNS metastases (HR 0.60, 95 CI: 0.41-0.87, P = 0.007), regardless the therapeutic strategy. Clinical behavior and prognosis of CNS metastases varies according to BC subtype. The association between LM disease and ER and/or PR positive tumors should be explored in upcoming studies. Also, these patients' prognosis depends on the availability of specific treatment options, therefore, innova-tive and effective therapeutic approaches are needed, in order to improve survival and quality of life of these patients. (c) 2022 Published by Elsevier Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号